Vudalimab is a monoclonal antibody commercialized by Xencor, with a leading Phase II program in Cervical Cancer. According to Globaldata, it is involved in 7 clinical trials, of which 1 was completed, 5 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Vudalimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Vudalimab is expected to reach an annual total of $104 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Vudalimab Overview
XmAb-717 is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC), spindle cell squamous cell carcinoma, anaplastic thyroid cancer, gall bladder cancer, fallopian tube cancer, cervical cancer and non-small cell lung cancer. It is administered through intravenous route. The drug candidate is a bi-specific monoclonal antibody that acts by targeting programmed cell death protein 1(PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). It is developed based on XmAb bi-specific/ Xtend Fc domains antibody engineering technology.
It was under development for the treatment of anal cancer, triple-negative breast cancer, squamous cell carcinoma of the anus, melanoma, high-grade neuroendocrine carcinoma, squamous cell carcinoma of the penus, hepatocellular carcinoma, urothelial cell carcinoma, renal cell carcinoma, colorectal cancer, endometrial cancer, non-small cell lung carcinoma, mesothelioma, gastroesophageal junction carcinomas, gastric cancer, small cell carcinoma of the lung, head and neck cancer squamous cell carcinoma, nasopharyngeal cancer, cholangiocarcinoma, basal cell carcinoma, ovarian cancer, peritoneal cancer, thymic carcinoma, vulvar cancer, salivary gland cancer, thymoma, Hodgkin lymphoma, anaplastic thyroid cancer and HER2 negative breast cancer.
Xencor Overview
Xencor is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Its other pipeline includes XmAb306/RO7310729, XmAb968 and XmAb662 (IL12-Fc), among others. Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Xencor is headquartered in Monrovia, California, the US.
The company reported revenues of (US Dollars) US$168.3 million for the fiscal year ended December 2023 (FY2023), an increase of 2.3% over FY2022. The operating loss of the company was US$138.6 million in FY2023, compared to an operating loss of US$82.6 million in FY2022. The net loss of the company was US$126.1 million in FY2023, compared to a net loss of US$55.2 million in FY2022.
The company reported revenues of US$17 million for the second quarter ended June 2024, an increase of 32.4% over the previous quarter.
For a complete picture of Vudalimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
